A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Rheumatoid ArthritisHealthy Volunteers
Interventions
DRUG

CE-224,535

one 250mg tablet, once in the morning in fasted state

DRUG

CE-224,535

2x250 mg tablets, once in the morning, in fasted state

DRUG

CE-224,535

4x250mg tablets, once in the morning, in fasted state

DRUG

CE-224,535

2x250mg tab, once in the morning, after being fed a high fat meal

DRUG

CE-224,535

4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.

DRUG

CE-224,535

4x125 mg IR once in the morning after being fed a high fat meal

DRUG

CE 224,535

2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state

DRUG

CE 224,535

2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY